Rite Aid skyrockets 50% on blockbuster earnings, its biggest jump in 10 years

Reuters/Noah BergerWilly Churchill leaves a Rite Aid store in Oakland, California.

  • Rite Aid on Thursday reported fiscal third-quarter earnings that handily beat Wall Street’s expectations.
  • Shares of the company surged as much as 50% in intraday trading on the news.
  • It marked the biggest intraday percentage gain for the struggling drugstore in more than 10 years.
  • The stock ended up more than 42%, its biggest increase since April 2009 on a closing basis.
  • Watch Rite Aid trade live on Markets Insider.

Rite Aid posted a big earnings beat on Thursday, and its stock soared as a result.

Shares of the drugstore surged as much as 50%, marking the biggest single-day percentage gain in more than 10 years. The increase came after its fiscal third quarter earnings report solidly beat analyst expectations.

Here’s what the company reported, versus what analysts surveyed by Bloomberg expected:

  • Adjusted earnings per share: $US0.54 reported versus $US0.07 (expected)
  • Revenue: $US5.46 billion reported versus $US5.42 (expected)

Net income for the third quarter was $US52.3 million, a 202% increase from the $US17.3 million that Rite Aid brought in during the same quarter a year earlier. The increase was primarily due to a $US55.7 million gain on debt retirements and an increase in adjusted EBITDA, the company said in a statement.

“While we are pleased with these results, we have important work ahead of us to put our company on a path to long-term sustainable growth,” said Rite Aid Chief Executive Officer Heyward Donigan, who took the top job in August after the previous CEO’s departure.

Even amid Thursday’s gains, Rite Aid shares are still down roughly 16% year-to-date. The company has struggled to win investor confidence as consumers increasingly turn to shopping online at places like Amazon for household items.

In addition, the pharmacy has suffered from decreasing prescription revenue as more people switch to generic drugs amid skyrocketing healthcare prices.

The company has a consensus price target of $US6.00 and zero “buy” ratings, one “hold” rating, and four “sell” ratings from Wall Street analysts, according to Bloomberg data.

RadMarkets Insider

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.